Benefits of Heart Recovery with Impella Showcased at ACC 2019
March 14 2019 - 8:00AM
Business Wire
The hemodynamic support of Abiomed’s (NASDAQ: ABMD) Impella
heart pump platform for high-risk PCI and treatment of cardiogenic
shock will be highlighted in more than 30 presentations and posters
at the American College of Cardiology’s (ACC) 68th Annual
Scientific Session March 16-18, in New Orleans.
Impella is the only FDA approved, safe and effective
heart pump for high-risk PCI, cardiogenic shock, and right
ventricular failure, and has supported more than 100,000 patients
in the United States, Germany and Japan. Abiomed remains
committed to advancing the field of heart recovery through clinical
research and support, education, and innovation. Impella will be
featured at ACC with:
- Presentations of Clinical Data
- Team-Based Treatment of Cardiogenic
Shock: A case-based session chaired by Perwaiz Meraj, MD and
Alexander Truesdell, MD will highlight the benefits of
multidisciplinary management of cardiogenic shock including the use
of best practices such as placing Impella before PCI.
- Kidney Protection with Impella:
An analysis by Michael Flaherty, MD from the ongoing, prospective
cVAD study shows an 85.5% lower incidence rate of AKI during
high-risk PCI when Impella is used (n=233, p<0.0001).
- Peripartum Cardiomyopathy: Uri
Elkayam, MD will present a poster presentation on the use of
Impella heart pump for management of women with peripartum
cardiogenic shock.
- Interactive Learning at Abiomed’s
BoothAbiomed’s booth #129 will feature clinical data and
hands-on learning with the Impella platform including Impella with
SmartAssist and Impella Connect, which
provide advanced technology and 24x7 clinical support services to
improve patient outcomes. Abiomed’s pipeline products including
Impella 5.5™, Impella ECP™, Impella BTR™, and expandable sheath1
will be included. Abiomed’s simulation training tool will allow
attendees to experience Impella CP heart pump insertion, placement,
and management.
- Potential Live High-Risk PCI Case
Using the Impella Heart PumpProtected PCI with Impella improves
quality of life and reduces post-discharge major adverse
cardiovascular and cerebrovascular events (MACCE) by 47% at 90
days2. Abiomed anticipates the potential broadcast of an elective
live Protected PCI case from Beth Israel Deaconess Medical Center
utilizing Impella during the conference.
For more information about Abiomed and heart recovery,
visit www.abiomed.com.
1. The Impella 5.5™ heart pump is not approved for use or sale
in the U.S. Impella ECP™ and Impella BTR™ heart pumps, and the
expandable sheath are in development and are not approved for use
or sale.2. O’Neill WW et al. Circulation. PROTECT II Randomized
Controlled Trial. 2012 Oct 2:126(14):1717-27.
ABOUT IMPELLA HEART PUMPS
The Impella 2.5 and Impella CP devices are FDA approved to treat
certain advanced heart failure patients undergoing elective and
urgent percutaneous coronary interventions (PCI) such as stenting
or balloon angioplasty, to re-open blocked coronary arteries. The
Impella 2.5®, Impella CP®, Impella CP® with SmartAssist, Impella
5.0® and Impella LD® are FDA approved heart pumps used to treat
heart attack or cardiomyopathy patients in cardiogenic shock, and
have the unique ability to enable native heart recovery, allowing
patients to return home with their own heart. To learn more about
the Impella platform of heart pumps, including their approved
indications and important safety and risk information associated
with the use of the devices, please visit:
www.protectedpci.com.
The ABIOMED logo, ABIOMED, Impella, Impella 2.5, Impella 5.0,
Impella LD, Impella CP, Impella RP, Impella Connect, and Recovering
hearts. Saving lives. are registered trademarks of ABIOMED, Inc. in
the U.S. and in certain foreign countries.
ABOUT ABIOMED
Based in Danvers, Massachusetts, Abiomed, Inc. is a leading
provider of medical devices that provide circulatory support. Our
products are designed to enable the heart to rest by improving
blood flow and/or performing the pumping of the heart. For
additional information, please visit: www.abiomed.com.
FORWARD-LOOKING STATEMENTS
This release contains forward-looking statements, including
statements regarding development of Abiomed's existing and new
products, the Company's progress toward commercial growth, and
future opportunities and expected regulatory approvals. The
Company's actual results may differ materially from those
anticipated in these forward-looking statements based upon a number
of factors, including uncertainties associated with development,
testing and related regulatory approvals, including the potential
for future losses, complex manufacturing, high quality
requirements, dependence on limited sources of supply, competition,
technological change, government regulation, litigation matters,
future capital needs and uncertainty of additional financing, and
other risks and challenges detailed in the Company's filings with
the Securities and Exchange Commission, including the most recently
filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q.
Readers are cautioned not to place undue reliance on any
forward-looking statements, which speak only as of the date of this
release. The Company undertakes no obligation to publicly release
the results of any revisions to these forward-looking statements
that may be made to reflect events or circumstances that occur
after the date of this release or to reflect the occurrence of
unanticipated events.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190314005241/en/
Tom LangfordDirector, Communications and Public
Relations978-882-8408tlangford@abiomed.com
Ingrid Goldberg WardDirector, Investor
Relations978-646-1590igoldberg@abiomed.com
ABIOMED (NASDAQ:ABMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
ABIOMED (NASDAQ:ABMD)
Historical Stock Chart
From Apr 2023 to Apr 2024